Low-dose IL-2 reduces IL-21


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
28 11 2022
Historique:
received: 10 04 2022
accepted: 17 10 2022
entrez: 28 11 2022
pubmed: 29 11 2022
medline: 1 12 2022
Statut: epublish

Résumé

Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) in type 1 diabetes using high-resolution single-cell multiomics and flow cytometry on longitudinally-collected peripheral blood samples. Our results confirm that iLD-IL-2 selectively expands thymic-derived FOXP3

Identifiants

pubmed: 36443294
doi: 10.1038/s41467-022-34162-3
pii: 10.1038/s41467-022-34162-3
pmc: PMC9705541
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Interleukin-2 0
interleukin-21 MKM3CA6LT1

Banques de données

figshare
['10.6084/m9.figshare.21395214']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7324

Informations de copyright

© 2022. The Author(s).

Références

J Autoimmun. 2015 Jan;56:66-80
pubmed: 25457307
Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305
pubmed: 24622415
Diabetologia. 2020 Sep;63(9):1808-1821
pubmed: 32607749
Immunity. 2010 Apr 23;32(4):457-67
pubmed: 20412756
Nat Rev Immunol. 2015 May;15(5):283-94
pubmed: 25882245
Wellcome Open Res. 2020 Mar 20;5:49
pubmed: 32399500
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
pubmed: 16585503
Diabetologia. 2019 Sep;62(9):1681-1688
pubmed: 31270583
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Ann Rheum Dis. 2016 Jul;75(7):1407-15
pubmed: 26324847
Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224
pubmed: 33662334
Blood Adv. 2019 Apr 9;3(7):984-994
pubmed: 30936059
Nat Commun. 2021 Apr 1;12(1):2029
pubmed: 33795689
Ann Rheum Dis. 2022 Dec;81(12):1685-1694
pubmed: 35973803
Front Immunol. 2021 Apr 01;12:648408
pubmed: 33868284
Diabetologia. 2015 Apr;58(4):781-90
pubmed: 25652388
J Autoimmun. 2015 Apr;58:48-58
pubmed: 25634360
Front Med (Lausanne). 2021 Sep 16;8:727987
pubmed: 34604264
Annu Rev Immunol. 2020 Apr 26;38:203-228
pubmed: 31986071
Genome Biol. 2014;15(12):550
pubmed: 25516281
N Engl J Med. 2011 Dec 1;365(22):2067-77
pubmed: 22129253
PLoS Pathog. 2021 Oct 7;17(10):e1009858
pubmed: 34618873
Bioinformatics. 2019 Jun 1;35(12):2084-2092
pubmed: 30395178
J Cell Physiol. 2022 Feb;237(2):1143-1156
pubmed: 34698381
BMJ Open. 2014 Jun 04;4(6):e005559
pubmed: 24898091
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nat Genet. 2007 Mar;39(3):329-37
pubmed: 17277778
AAPS J. 2016 Jan;18(1):156-70
pubmed: 26408308
Science. 2021 Jul 30;373(6554):506-510
pubmed: 34326231
Mol Ther. 2014 Jul;22(7):1388-1395
pubmed: 24686272
Diabetes. 2015 Jun;64(6):2172-83
pubmed: 25576057
Blood. 1997 May 1;89(9):3148-54
pubmed: 9129017
Front Immunol. 2021 Apr 09;12:653974
pubmed: 33897702
PLoS Med. 2016 Oct 11;13(10):e1002139
pubmed: 27727279
Nat Med. 2017 May;23(5):579-589
pubmed: 28368383
Wellcome Open Res. 2021 Jun 14;6:149
pubmed: 35509371
Front Immunol. 2019 Nov 08;10:2606
pubmed: 31781109
Ann Rheum Dis. 2020 Jan;79(1):141-149
pubmed: 31537547
J Autoimmun. 2020 Aug;112:102466
pubmed: 32414606
Science. 2021 Jul 16;373(6552):
pubmed: 34437125
Genome Med. 2016 Jul 19;8(1):76
pubmed: 27435189
Immunol Cell Biol. 2012 Feb;90(2):159-67
pubmed: 21606942
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Immunol Rev. 2016 May;271(1):246-59
pubmed: 27088919
J Clin Invest. 2011 Nov;121(11):4303-10
pubmed: 22019586
BMJ Open. 2018 Sep 17;8(9):e022452
pubmed: 30224390
J Immunol. 2000 Sep 1;165(5):2738-47
pubmed: 10946305
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282826
J Immunol. 2013 Mar 15;190(6):2554-66
pubmed: 23418630
Immunity. 2008 May;28(5):687-97
pubmed: 18468463
Genome Med. 2020 Jun 24;12(1):55
pubmed: 32580776
Nat Rev Rheumatol. 2021 Dec;17(12):749-766
pubmed: 34728817
J Autoimmun. 2017 Nov;84:75-86
pubmed: 28747257
J Immunol. 1998 Sep 1;161(5):2465-72
pubmed: 9725245
Nat Commun. 2020 Mar 5;11(1):1201
pubmed: 32139671
Front Immunol. 2016 Jun 30;7:262
pubmed: 27446091
JCI Insight. 2016 Nov 3;1(18):e89278
pubmed: 27812545
Nat Genet. 2021 Jul;53(7):962-971
pubmed: 34127860
J Clin Invest. 2015 Jan;125(1):292-303
pubmed: 25485678
BMJ Open. 2015 Dec 08;5(12):e009799
pubmed: 26646829
Diabetes. 2012 Jan;61(1):14-22
pubmed: 22187370
Immunity. 2012 May 25;36(5):847-56
pubmed: 22464171
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Nat Genet. 1993 Aug;4(4):404-9
pubmed: 8401590
J Autoimmun. 2021 Aug;122:102689
pubmed: 34224936
J Immunol. 2003 Jun 1;170(11):5470-4
pubmed: 12759423
Blood Adv. 2019 Sep 10;3(17):2550-2561
pubmed: 31471324
Cell Death Differ. 2021 Dec;28(12):3357-3370
pubmed: 34183782
J Immunol. 2013 Jul 1;191(1):154-63
pubmed: 23720813
JAMA Dermatol. 2014 Jul;150(7):748-51
pubmed: 24872229
Nat Med. 2016 Sep;22(9):991-3
pubmed: 27500725
Nat Immunol. 2016 Aug;17(8):976-84
pubmed: 27376469

Auteurs

Jia-Yuan Zhang (JY)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Fiona Hamey (F)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Dominik Trzupek (D)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Marius Mickunas (M)

Department of Immunobiology, King's College London, School of Immunology and Microbial Sciences, London, UK.

Mercede Lee (M)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Leila Godfrey (L)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Jennie H M Yang (JHM)

Department of Immunobiology, King's College London, School of Immunology and Microbial Sciences, London, UK.

Marcin L Pekalski (ML)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Jane Kennet (J)

Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Biomedical Campus, Cambridge, UK.

Frank Waldron-Lynch (F)

Vertex Pharmaceuticals, Vertex Cell & Gene Therapies, Boston, MA, USA.

Mark L Evans (ML)

Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Biomedical Campus, Cambridge, UK.

Timothy I M Tree (TIM)

Department of Immunobiology, King's College London, School of Immunology and Microbial Sciences, London, UK.

Linda S Wicker (LS)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

John A Todd (JA)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. john.todd@well.ox.ac.uk.

Ricardo C Ferreira (RC)

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. ricardo.ferreira@well.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH